What is Cerebral Therapeutics?
Cerebral Therapeutics is a specialized biotechnology firm dedicated to overcoming the blood-brain barrier to treat uncontrolled neurological conditions. The company utilizes advanced micro-dosing delivery systems to ensure precise medication administration directly to targeted sites within the brain. This innovative approach aims to improve patient outcomes for a range of debilitating conditions, including epilepsy, Parkinson's disease, and Alzheimer's. By bridging the gap between complex drug delivery and clinical efficacy, Cerebral Therapeutics is redefining the standard of care for neurological disorders, moving beyond systemic treatments toward highly localized, effective therapeutic interventions.
How much funding has Cerebral Therapeutics raised?
Cerebral Therapeutics has raised a total of $86M across 3 funding rounds:
Series A
$11M
Series B
$35M
Series C
$40M
Series A (2019): $11M with participation from Granite Point Capital Management, L.P. and Vivo Capital, LLC
Series B (2020): $35M led by RA Capital Management, Granite Point Capital Management, Vivo Capital, and Perceptive Advisors
Series C (2022): $40M supported by Perceptive Advisors, Lynx1 Capital Management, Vivo Capital, Granite Point Capital, and RA Capital Management
Key Investors in Cerebral Therapeutics
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
Vivo Capital
Vivo Capital founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
What's next for Cerebral Therapeutics?
With the recent influx of capital, Cerebral Therapeutics is well-positioned to accelerate its clinical development pipeline and expand its research into new therapeutic areas such as obesity and anxiety spectrum disorders. The company's strategic roadmap focuses on scaling its proprietary delivery platform to support broader commercialization efforts. As the firm transitions from development to advanced clinical stages, the focus will remain on validating its micro-dosing technology across diverse neurological indications, ensuring that its innovative solutions reach patients in need while maintaining a robust intellectual property portfolio.
See full Cerebral Therapeutics company page
